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ABSTRACT  
Motivation: Analysis of relationships of drug structure to biological 
response is key to understanding off-target and unexpected drug 
effects, and for developing hypotheses on how to tailor drug thera-
pies. New methods are required for integrated analyses of a large 
number of chemical features of drugs against the corresponding 
genome-wide responses of multiple cell models. 
Results: In this paper, we present the first comprehensive multi-set 
analysis on how the chemical structure of drugs impacts on ge-
nome-wide gene expression across several cancer cell lines (CMap 
database). The task is formulated as searching for drug response 
components across multiple cancers to reveal shared effects of 
drugs and the chemical features that may be responsible. The com-
ponents can be computed with an extension of a very recent ap-
proach called Group Factor Analysis (GFA). We identify 11 compo-
nents that link the structural descriptors of drugs with specific gene 
expression responses observed in the three cell lines, and identify 
structural groups that may be responsible for the responses. Our 
method quantitatively outperforms the limited earlier studies on 
CMap and identifies both the previously reported associations and 
several interesting novel findings, by taking into account multiple cell 
lines and advanced 3D structural descriptors. The novel observa-
tions include: previously unknown similarities in the effects induced 
by 15-delta prostaglandin J2 and HSP90 inhibitors, which are linked 
to the 3D descriptors of the drugs; and the induction by simvastatin 
of leukemia-specific anti-inflammatory response, resembling the 
effects of corticosteroids. 
Contact: suleiman.khan@aalto.fi, samuel.kaski@aalto.fi  
1 INTRODUCTION 
Modeling and understanding the diverse spectrum of cellular re-
sponses to drugs is one of the biggest challenges in chemical sys-
tems biology. Some of the responses can be predicted for targeted 
drugs, which have been designed to bind to a specific protein that 
triggers the biological response. The binding of a drug to a target 
largely depends on the structural correspondence of the drug mole-
cule and the binding cavity of the target molecule which can be 
modeled in principle, given ample computational resources. Off-
target effects are harder to predict. They are dependent on the cell 
types, individual genetic characteristics and cellular states making 
the spectrum of responses overwhelmingly diverse. The less well 
known the drug’s mechanism of action and the characteristics of 
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the disease, the harder the prediction from first principles becomes. 
The most feasible way to approach this challenge in an unbiased 
way, which does not require prior knowledge of all on- and off-
target interactions of drugs, is to collect systematic measurements 
across different drugs, cell types, and diseases, and search for re-
sponse patterns correlating with the characteristics of the drugs. 
The patterns found can be used as evidence for hypotheses on un-
derlying action mechanisms, or directly in predicting the respons-
es. 
The Connectivity Map (CMap; Lamb et al., 2006) described the 
basis for a data-driven study of drug-effect relationships at a ge-
nome-wide level. CMap hosts the largest collection of high-
dimensional gene expression profiles derived from treatment of 
three different human cancer cell lines with over one thousand 
drugs. The CMap data have been used in a multitude of studies 
revealing new biological links between drugs and between drugs 
and diseases. Genome-wide gene expression responses from the 
CMap have been used to discover clusters of drugs having similar 
mechanisms of action, resulting in novel findings, such as effects 
of heat shock protein (HSP) inhibitors and identification of modu-
lators of autophagy (Iorio et al., 2010). The CMap data have also 
been successfully used in large scale integrative studies including 
the analysis of regulation of drug targets (Iskar et al., 2010), hERG 
annotations to predict novel inhibitors (Babcock et al., 2013) and 
drugs’ interactions with protein networks (Laenen et al., 2013). 
Quantitative structure activity relationship analysis (QSAR; 
Cramer et al., 1988) is a widely adopted approach to studying drug 
responses. Traditionally, univariate biological activities are pre-
dicted using a range of methods, including classical regression, 
Support Vector Machines, and Random Forests. The key challenge 
when moving from traditional QSAR to systems wide analysis of 
chemical effects is how to relate structural features to genome-
wide cellular responses. 
Integration of chemical structures with genome-wide responses has 
become a major research direction in Chemical Systems Biology 
(Iskar et al., 2012; Xie et al., 2012). Keiser et al. (2009) studied 
structural similarities between ligand sets while Klabunde et al. 
(2005) used protein-ligand complexes to predict off-targets. To 
infer potential indications for drugs, Gottlieb et al. (2011) com-
bined similarities from chemical structures, gene expression pro-
files, protein targets and several other datasets. Atias et al. (2011) 
modeled linkage between structural descriptors of drugs and their 
side effects using Canonical Correlation Analysis (CCA; Hotelling, 
1936). Structures have also been used with genomic datasets to 
predict toxicity and complex adverse drug reactions (Russom et 
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al., 2013). Recently, Menden et al. (2013) combined structures of 
drugs and mutation information of cell lines to predict drug cyto-
toxicity in a series of cell lines. 
Relationships between structural descriptors of drugs and their 
gene expression profiles have also been studied. Cheng et al. 
(2010) examined similarities between chemical structures and 
molecular targets of 37 drugs that were clustered based on their 
bioactivity profiles. Low et al. (2011) classified 127 rat liver sam-
ples to toxic vs non-toxic responses, based on combined drug-
induced expression profiles and chemical descriptors, and identi-
fied chemical substructures and genes that were responsible for 
liver toxicity. In a broader setting, when the goal is to find depend-
encies between two data sources (chemical structures and genomic 
responses), correlation-type approaches match the goal directly, 
and have the additional advantage that a pre-defined classification 
is not required. Khan et al. (2012) generalized structure-response 
analysis to multivariate correlations with Canonical Correlation 
Analysis (CCA) on the CMap. Due to the limitations of classical 
CCA, their study was restricted to a limited set of descriptors (76) 
and genomic summaries (1321 genesets), and did not attempt to 
take into account the data from three separate cell lines. 
In this paper we present the first probabilistic approach to the prob-
lem of integrated analysis of effects of chemical structures across 
genome-wide responses in multiple model systems. We extend the 
earlier work in three major ways: (i) Instead of using only two data 
sources (as in classical CCA), we used the recent Bayesian Group 
Factor Analysis method (GFA; Virtanen et al., 2012) that general-
izes the analysis to multiple sources, here three cell lines and two 
sets of chemical descriptors. (ii) Our Bayesian treatment with fea-
ture-level priors enabled us to cope better with the uncertainties in 
the high-dimensional data. (iii) We included a more informative set 
of 3D chemical descriptors to complement the widely used 2D 
fingerprints which are recognized to only explain limited aspects 
of drugs (Schneider, 2010).  
Our goal was to uncover the big picture of relationships between 
chemical structure parameters and genome-wide responses, in a 
data-driven fashion (Fig. 1). The data came from CMap, 11,327 
gene-wide responses in three cell lines (HL60-Blood 
Cancer/Leukemia, MCF7-Breast Cancer and PC3-Prostate Cancer; 
Lamb et al., 2006), and from two sets of chemical descriptors: 780 
3D Pentacle descriptors of drugs (Duran et al., 2008) and 2,769 
functionally relevant structural fragments (FCFP4; Glen et al., 
2006) as 2D fingerprints of the drugs. These five datasets consist 
of samples from the 682 drug treatments, coupled by the detailed 
drug identity. We analyzed the statistical relationships between the 
datasets by decomposing them into a set of interpretable 
components. Our method quantitatively outperformed previous 
studies, thereby validating the approach. We rediscovered findings 
reported earlier as well as identified novel drug associations and 
detailed structure-response relationships. 
2 METHODS 
2.1 Gene Expression Datasets 
We used the Connectivity Map (Lamb et al., 2006) gene expression data as 
a measure of the biological response of the three cancer cell lines to drug 
treatments, forming the gene expression datasets. The Connectivity Map 
hosts over 7100 gene expression profiles including technical replicates 
treated with 1309 drugs and is the largest available resource of its kind. 
Responses from a subset of these drugs (682) were measured on all of the 
three cell lines, namely HL60 (Leukemia), MCF7 (Breast Cancer) and PC3 
(Prostate Cancer cell line). 
We obtained the raw gene expression profiles from the Connectivity Map 
and used the data from the most abundant microarray platform (HT-HG-
U133A). The data were preprocessed using RMA (Irizarry et al., 2003) and 
drug-treatment vs. control (log2) differential expression was calculated 
 
Fig. 1. Overview of the symmetric multi-structure to multi-response decomposition. A) The five datasets spanning 682 paired drugs are B) decomposed into 
components by GFA. Components of Type 1 represent shared patterns in both chemistry and biology while Type 2 describes biology-only or chemistry-only 
variation (not as useful in our case). C) Each shared component identifies key structures and genes of an underlying biological process. 
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batch-wise (Khan et al., 2012). Technical replicates were merged by taking 
the mean of each gene. This resulted in gene expression profiles for the 682 
drugs having measurements over all three cell lines. To reduce noise we 
approximated the approach of Iorio et al. (2010) for our setting, by retain-
ing the expression of top 2000 up and down regulated genes for each sam-
ple, while considering the rest to be noise (set to zero). These profiles 
formed three biological response datasets (one for each cell line), each 
being a differential gene expression matrix of 682 drugs times 11,327 
genes. 
2.2 Chemical Descriptor Datasets 
The chemical space of drugs was represented using two different types of 
chemical descriptors, namely the 2D fingerprints ‘FCFP4’ and 3D de-
scriptors ‘Pentacle’. The FCFP4 (Functional Connectivity Fingerprints of 
radius 4; Glen et al., 2006) are circular topological fingerprints designed 
specifically for structure-activity modeling and similarity searching. They 
are rapidly computable and heavily used in a wide variety of applications 
(Rogers and Hahn, 2010). Each dimension of the fingerprints represents a 
certain 2-dimensional fragment of the compounds, interpretable as presence 
of certain substructures, typically stereochemical information, and allows 
easy visual inspection of structures. Therefore, FCFP4 can be used to iden-
tify the core 2D substructures that make compounds structurally similar and 
are responsible for biological activity. 
The more complex 3-dimensional descriptors Pentacle (Duran et al., 2008) 
capture the functional properties of the compounds using molecular interac-
tion fields. They are able to group together compounds with very dissimilar 
chemical structures and yet having the same type of molecular field proper-
ties. This is especially important in our study where the aim is to find small 
molecules that share biological functions despite structural dissimilarity. 
Most of the traditional fingerprints, like MACCS and FCFP4, are superior 
to recognize 2D structural similarity but unfortunately unable to recognize 
structurally unrelated and yet biologically similar compounds binding into 
the same binding pocket. The opposite is true with most (if not all) field-
based similarity methods like Pentacle, which find more effective distant 
similarities; therefore we decided to combine both approaches. In the earli-
er work, Khan et al. (2012) had used VolSurf descriptors to represent mo-
lecular properties. While VolSurf is an optimal method for physicochemi-
cal properties estimation it is not able to describe pharmacophore features 
extensively, unlike the Pentacle descriptors, and thus is not an option in our 
study. 
Pentacle field distance descriptors were computed using Pentacle v 1.0.4 
(http://www.moldiscovery.com/soft_pentacle.php), by Molecular Discov-
ery. The descriptors were calculated for all the available 10 probe sets, 
namely D², O², N², T², DO, DN, DT, ON, OT, NT, where D is Dry Probe to 
represent hydrophobic interactions, O is carbonyl oxygen probe to repre-
sent H-bond donor feature of the molecules and N flat probe of Nitrogen is 
the H-bond acceptor while T is TIP probe representing shape of the mole-
cule, in terms of steric hot spots. For each probe set 78 descriptors were 
obtained, representing the interaction potentials of probes at different dis-
tances, resulting in 780 descriptors in total. Higher interaction potential 
values indicate stronger interaction of compounds with Pentacle probes. 
This results in a 682 x 780 data matrix, with each row being a drug and the 
780 columns representing the Pentacle descriptors. This forms the first 
chemical dataset in our study. 
The 2D functional connectivity fingerprints (FCFP4) represent the chemi-
cals as structural fragments. In FCFP, the fragments are not predefined, 
rather computed dynamically and thus can represent variation in novel 
structures. The FCFP4 fingerprints were computed using Pipeline Pilot 
Student Edition software (http://accelrys.com/products/pipeline-pilot/), by 
Accelrys. A total of 2,769 unique structural fragments are found and the 
fingerprints are represented as a matrix of 682 compounds x 2,769 frag-
ment descriptors. This forms the second chemical dataset in our study. 
2.3 Model: Group Factor Analysis (GFA) 
We search for relationships between chemical descriptors and biological 
responses, as clues to the key underlying biological processes. Group Fac-
tor Analysis (GFA) is a model designed to capture such relationships (sta-
tistical dependencies) by explaining a collection of datasets (“views”) by a 
set of factors or components, which form a combined low-dimensional 
representation (Virtanen et al., 2012). In the multi-view setting, each com-
ponent is active in a subset of the datasets, and is a simplified model of an 
underlying process visible in those sets. The task solved by GFA is to sepa-
rate the shared components that capture the structure-biology relationships 
from the rest of the data: the former are visible in all or a subset of the 
datasets, whereas components active in a single view describe variation 
specific to that particular view or noise. 
Given a collection of M datasets ( ) 11    N DX R ×∈ … ( )    Mm N DX R ×∈ , consist-
ing of N co-occurring samples ( )mnx , GFA finds a set of latent components 
(with upper limit K, see below). Each dataset is assumed to have been 
generated as a linear combination of latent components   N KZ R ×∈ , with 
weights of the combination given by a loadings matrix ( )    mm D KW R ×∈ : 
Assuming normal distributions for simplicity, the model is: 
( ) ( ) ( )( ) ~ ,  ,m m mn nN Σx W z   
    z
n
 ~ N 0, I( ) , (1) 
where nz is the n
th
 row of Z, and ( )mΣ is a diagonal noise covariance matrix. 
GFA is special in that the projections W are required to be group-wise 
sparse, i.e., all the elements ( ):,
m
kW are set to zero for the components k that 
are not active in the mth dataset. The components with non-zero projections 
between two or more views capture dependencies between the views.  
To increase the interpretability of the model we extend GFA by introducing 
element-wise sparsity in addition to the group-sparsity for the projection 
matrices, matching the biological prior assumption that each process typi-
cally activates only a subset of genes. We introduce element-wise Automat-
ic Relevance Determination (ARD; Neal, 1996) prior for the projection 
weight matrices, pushing irrelevant weight values ( )
,
m
d kW towards zero and 
making each component element-wise sparse. For the group sparsity we 
apply the group spike and slab prior (Klami et al., 2013) where the binary 
variable ( )mkH controls the activity of the kth component in the group m. The 
prior is  
( ) ( ) ( )( ) ( )( )1, , 0 ~ 0,( ) 1 ,m m m md k k d k kN α δ− + −W H H  
( ) ( ) ~ ,mk kBernoulli piH  
( )      ~ , ,k Beta a bpi pipi  
( ) ( ),   ~ , .md k Gamma a bα αα  
(2) 
If ( )mkH  becomes zero, all values in ( ):,
m
kW will be set to zero. To complete 
the model description, we set an uninformative prior to the diagonal ele-
ments of the precision matrix ( ) 1( )m −Σ .  
We represent our (M=5) datasets as matrices of drugs vs. features. The 
rows represent the samples (drugs) and the columns are the features (genes 
or chemical descriptors). Drugs are paired in all the views, i.e., a row in all 
matrices correspond to the same drug. A total of N = 682 drugs were used 
in the study. The features of the chemical descriptors, Pentacle (m=1) and 
FCFP4 (m=2) are D1 = 780 Pentacle probe fields and D2 = 2,769 fragment 
structures, respectively. The biological responses of the three cell lines 
(m=3,4,5) are represented by differential expression of Dm  = 11,327 genes 
each.  
The hyperparameters of the gamma distribution were set to values 
3(1e )− corresponding to an uninformative symmetric prior, while the hy-
perparameters of the spike and slab were set to  , 1a bpi pi = . All remaining 
model parameters are learned from the data using Gibbs sampling. The 
number of components is optimally learned from data by initializing K to 
be large enough, such that sparsity assumptions push some to be inactive. 
Here for computational reasons we set K=80, a value significantly larger 
than the actual number of shared components, and let the noise model 
represent the rest of the data. For sampling, we ran 10 chains and selected 
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for further analysis the one having its likelihood closest to the mean of non-
outlier chains. The first 5000 samples were discarded as the burn-in, and 
the chain was run for 1000 more iterations, with a thinning factor of 5. The 
mean value of the samples was used as a representation of the model. As a 
sanity check, we verified that our shared components had over 70% simi-
larity with the second (non-used) chain. 
For interpretation we represent each component by listing the high-valued 
latent scores z and projection values W. For the latent scores we performed 
a permutation test to detect the most significantly (q-value < 0.05) activated 
drugs, while for the projections we inspected the top 30 elements. 
3 RESULTS 
Fig. 2 gives an overview of the types of components discovered by 
the model. For studying structure-activity relationships, the most 
important are the components shared by one or more chemical 
view and one or more of the cancer subtypes. The components 
active in only the expression datasets represent drug responses not 
captured by the used chemical descriptors, and components only 
active in the chemical datasets represent biologically irrelevant 
structural variance. Additionally, components active in only a sin-
gle dataset may represent dataset-specific noise. We found a total 
of 11 shared components which will be discussed below. The de-
tailed structure-response relationships discovered from all the 
shared components are visualized in Supplementary Figure S1 and 
tabulated in a usable format in Supplementary Table S2. 
3.1 Validation via Chemical Biology Ontology 
We started by quantitatively evaluating how closely related the 
drugs in the shared components are in terms of known chemical 
biology relationships, and compared our data with those of two 
previous studies that investigated drug actions using the CMap 
database (Iorio et al., 2010; Khan et al., 2012). 
The established chemical biology relationships were obtained from 
the ontology, Chemical Entities of Biological Interest (ChEBI; 
Degtyarenko et al., 2008), which is the largest such ontology of 
small compounds. ChEBI links compounds with respect to Chemi-
cal structure, Biological roles they are known to play, and their 
Applications. Examples of classifications are antibiotic, coenzyme 
and agonist (biological); donor, ligand, inhibitor (chemical), and 
pesticide, anti-asthmatic (applications). ChEBI was downloaded as 
a graph containing paths between 328 of our compounds via 611 
ontology terms (http://www.ebi.ac.uk/chebi/).  
The average similarity (inverse path distance) of drugs within the 
shared GFA components was consistently higher than the corre-
sponding similarities of Khan et al., (2012), Iorio et al., (2010) and 
random sets of compounds (Fig. 3). The largest path length (16) in 
ChEBI linked all drugs, while the smallest (2) linked only the most 
similar. Interestingly, the difference in GFA and others on small 
path lengths was higher than that on larger ones, indicating that 
drugs closely connected in ChEBI were even better found by GFA. 
3.2 Component Interpretations 
We next analyzed the shared components in detail. Each compo-
nent connects a set of structural drug properties and gene expres-
sion changes, forming a hypothesis of a structure activity relation-
ship. A component can be characterized by the set of drugs that 
activate it the most, and by the set of genes that are expressed dif-
ferentially when the component is active. 
We first compared the findings to the two other studies that have 
investigated drug actions using the CMap database (Iorio et al., 
2010; Khan et al., 2012). Out of the 11 shared GFA components, 
the majority of the drugs in 7 components were similar to the clus-
ters found by Iorio et al. (2010), while 3 components captured 
structurally driven cell-specific responses they had missed. Com-
pared to the other earlier study (Khan et al., 2012), the majority of 
the drugs in 6 out of the 11 GFA components matched a corre-
sponding structure-response subcomponent of Khan et al., (2012), 
again indicating conformance to known results. Our components 
also revealed several novel drug actions due to cell-type specificity 
and advanced 3D descriptors that were missed by both of these 
earlier studies, and are presented below.  
Detailed interpretation of all the 11 shared components is present-
ed in Supplementary Table S1. The components were numbered in 
the order of the amount of variation they captured; the cell line 
specific components identified by the model were separately or-
dered with the prefix SP. One component (SP3) captured outlier 
response of a single drug, and was omitted from further analysis.  
The majority of the components captured effects shared among all 
the three cell lines, while five components had responses which 
were either cell-line-specific (components SP1, SP2, SP4), domi-
nant in a specific cell line (component 7), or revealed some cell-
line-specificity indications for an interesting drug (component 1). 
The 2D structural features were active in most components, identi-
 
Fig. 2. Summary of the GFA components. The plot demonstrates activity 
(black is active) of each component (y-axis) over the 5 input datasets (x-
axis). Each component is active in some or all of the  datasets. Components 
shared (active) by both chemical descriptor and expression datasets capture 
structure-response relationships. 
 
Fig. 3. Quantitative Validation of chemical biology similarity of drugs in 
shared GFA Components. Drugs in the same GFA Component had a 
consistently higher mean average similarity (y-axis) in ChEBI than either 
of the earlier studies, and random sets of compounds, over the entire range 
of ChEBI path lengths (x-axis). Error bars represent one standard deviation 
over 1000 randomly generated sets. 
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fying similarities in structurally analogous drugs. The pentacle 
descriptors captured similarities in five components, four of which 
indicated novel responses of drugs that have not been reported 
before. We discuss these four novel components in detail below. 
One of these had cell-line-specific effects (SP2), while the remain-
ing cell-line-specific components (SP1 and SP4) are summarized 
in Table 1.  
Component 1 was characterized by cardenolides. The top 7 drugs 
of the component, lanatoside C, digitoxigenin, digoxin, digoxigen-
in, ouabin, helveticoside and strophantidin belonged to this class. 
The primary activity of the other drugs anisomycin, lycorine and 
cicloheximide is protein synthesis inhibition, and bisacodyl is used 
as a laxative through stimulation of secretion in the colon. 
Cardenolides act on Na+/K+ pumps and are known for ion flux 
alterations. Interestingly, the other compounds of Component 1 
also appeared to affect membrane potassium ion flux. Bisacodyl 
and anisomycin activate K+ flux, lycorine is known to reduce 
membrane potential (indicative of potassium efflux) and, indicative 
of affecting K+, emetine needs to be administered with potassium 
to reduce cardiotoxicity. Interestingly, bisacodyl exhibited the 
response in MCF7 and PC3 cells only, suggesting that its target 
may be expressed selectively. 
On the structural side, the top 4 FCFP4 fragments collectively 
represented the correct core 2D response triggering substructure in 
all the 7 cardenolides, as detailed in Fig. 4. The other two key 
drugs, bisacodyl and anisomycin, were different from cardiac gly-
cosides in terms of 2D structures, but the Pentacle descriptors indi-
cated potential field similarities on ON, OT and NT probes. These 
probes referred to existence of common structural pharmacophoric 
features: hydrogen-bonding and shape-related features. The 3D 
descriptors may therefore indicate that these drugs do indeed bind 
the same ion channels as the Cardenolides. 
Component 3 captured protein synthesis inhibition. All drugs in 
the component are known to inhibit protein synthesis but each in a 
different way. The only exception, alexidine, is a derivative of 
clorhexidine, which is used as an antibacterial mouth wash. Inter-
estingly, it has been described to have anti-cancer cell activity 
through an unknown target (Yip et al., 2006). The model identified 
pentacle probe fields of D2, DO and DT (shape and lipophilicity 
related probes) that relate alexidine’s protein synthesis inhibition 
response with the known protein synthesis inhibitors.  
Component 5 was HSP90 inhibition response. The component 
contains the three very similar drugs geldanamycin, tanespimycin, 
alvespimycin, and on the 2D structure level very dissimilar 15-
delta prostaglandin J2 (PGJ2) and puromycin. Geldanamycin and 
its two analogs tanespimycin and alvespimycin are heat shock 
protein (HSP) 90 inhibitors and the latter two have been explored 
in the clinic as anti-cancer drugs. PGJ2 has also been described as 
having anti-cancer activity through an unknown mechanism, caus-
ing inhibition of several cancer survival signals. Puromycin is re-
ported as an aminonucleoside antibiotic with a primary function of 
terminating ribosomal protein translation. At the response level, 
this component appeared to be strongly inducing a heat shock re-
sponse with many HSP and related genes being up-regulated (see 
Fig. 5, left). The expression profile very strongly indicated that 
PGJ2 and puromycin are also inhibiting HSP90. PubChem drug-
target data demonstrates that HSP90 targets have been reported as 
active in geldanamycin and its derivatives, while untest-
ed/unspecified for both puromycin and prostaglandin.  
On the structural side, the 2D descriptors confirmed that puromy-
cin and prostaglandin are dissimilar to the three geldanamycin 
analogs. However, the Pentacle descriptors clearly indicated that 
N2, DN and NT fields shared a very strong pattern across all the 
five drugs. The patterns were only visible in features of smaller 
distances of these large molecules, indicating that only a small 
region of these compounds (polar atoms of all compounds) created 
Table 1. Shared components having cell-line-specific response. The com-
ponents (rows) are summarized by their top drugs (column 1), biological 
response (column 2) and the structural properties (column 3). 





mycin a protein syn-
thesis inhibitor. 8-
azaguanine has been 
used in leukemia 
(Colsky et al., 1955). 
Protein synthesis inhibition in 
HL60 and PC3 cells only. It 
could be interesting to explore 
8-azaguanine as an anti-Prostate 
Cancer drug. In a recent study 
Wen et al. (2013) also indicated 
8-azaguanine for potential ther-





SP4 Anti-Estrogen Drugs Response visible in MCF7 (es-




Fig. 4. Structure identification in Component 1. Left: The top 4 FCFP4 Structural Fragments identified by the model as strongly relating to the response of 
the drugs (right). When combined, these fragments represent the core response triggering structure steroid backbone (shaded grey) in all the cardenolides. 
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the activity, while the rest of the structure is just needed to main-
tain the shape. This fitted well with the observation that the drugs 
are overall structurally very dissimilar. At the smaller distances the 
structure responsible for biological response was characterized by 
N2: ligands hydrogen bonding capacity, DN: hydrogen bonding 
and lipopholicity and NT: hydrogen bonding/shape based de-
scriptors. In geldanamycin and prostaglandin this distance (see Fig. 
5 where N2 descriptor is plotted) was connected to polar ring-
atoms and more precisely corresponding H-bonding positions. 
These same positions, although in a different conformational ar-
rangement (but with almost identical distance) are critical in the 
binding of geldanamycin to HSP90. Hence, while the expression 
data strongly argues for PGJ2 inhibiting HSP90 activity at some 
level, the structural information does suggest that this effect could 
be through a direct binding to HSP90 enzymes. 
Component SP2 is a corticosteroid component, but additionally 
captured very similar responses by other steroids such as etynodiol 
as well as the surprisingly different drugs simvastatin and rep-
aglinide. Corticosteroids are anti-inflammatory and typically used 
against immune responses. Concentrations in the micromolar range 
were typically used in the CMap data, which is very high, com-
pared to the nanomolar affinities to the corticosteroid receptor 
primary targets. The response in this component was largely domi-
nant in HL60 cells (Fig. 6) and lightly observed in PC3 while none 
at all was observed in MCF7, indicating that the relevant target or 
signal may be selectively expressed in HL60. Both simvastatin (a 
cholesterol-lowering HMG-CoA inhibitor) and repaglinide (a dia-
betes drug) are highly dissimilar at the 2D level when compared to 
the corticosteriods, but both interestingly have been reported to 
have anti-inflammatory activities, likely due to targets other than 
the primary target(s). Once again, Pentacle descriptors capture the 
underlying similarities between these drugs through NT and N2 
fields suggesting that the common gene expression patterns in-
duced by the different drugs (corticosteroids, simvastatin and rep-
aglinide) affect the same targets, either primary or off-targets. 
4 CONCLUSIONS AND DISCUSSION 
We extended the drug response analysis paradigm from standard 
QSAR, of relating drug properties and univariate responses, to 
finding relationships between specific structural descriptors of 
drugs with the genome-wide responses they elicit in multiple cell 
lines. The task was formalized as discovering dependencies be-
tween multiple datasets, and addressed using the state-of-the-art 
method Group Factor Analysis (GFA). The approach identified 
structure-genomic response relationships as underlying compo-
nents of the data, and can be used as a tool for exploring such rela-
tionships from large-scale measurement datasets.  
We quantitatively validated our structure-response components 
over the established chemical-biology relationships of ChEBI and 
found them to be better than earlier studies (Iorio et al., 2010; 
Khan et al., 2012) that did not account for separate cell lines and 
advanced 3D chemical descriptors. Moreover, several drug groups 
we identified were consistent with earlier studies while several 
revealed significantly interesting novel findings earlier studies had 
missed, demonstrating that our approach is viable for explorative 
multi-set structure-activity analysis. These novel findings were 
clearly attributed to separating cell line identities and advanced 3D 
descriptors in our formulation. In a different setting, Yera et al., 
(2011) found 3D similarity to be more important for off-target 
identification and this was partially supported by our study as well. 
However, since the used methods are not identical and since in our 
approach biological profile (gene expression) was also actively 
used, this question remains open. 
The discovered components revealed interesting new findings of 
potential importance for revealing novel action mechanisms of 
drugs. The 2D fingerprints highlighted important core structural 
groups primarily responsible for activity of similar drugs, such as 
the identification of the steroid backbone in cardiac glycosides and 
aromatic ring in HDAC inhibitors. The joint analysis of data from 
multiple cell lines with advanced 3D Pentacle descriptors allowed 
us to identify relationships between drugs that were not known 
earlier. If validated, this suggests an approach that could signifi-
cantly help in medicinal chemistry and drug design. For example, 
 
Fig. 5. Component 5 identified a novel HSP90 response of prostaglandin. Left: Gene expression response of the top 7 drugs in the three cell lines (y-axis), 
over the top genes (x-axis) of the component, demonstrates HSP genes being strongly up-regulated by the HSP90 inhibitors and by the strikingly very 
different puromycin and prostaglandin. Right: N2 descriptor in geldanamycin and prostaglandin connected to several polar ring-atoms (red and blue). The 
Pentacle feature (N2 distance range) found by GFA as related with HSP gene expression is represented with the yellow line. 
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our data led to the identification of a previously unknown and nov-
el shared mechanism of 15-delta prostaglandin J2 (PGJ2) and heat 
shock protein (HSP90) inhibitors. Interestingly, PGJ2 and related 
prostaglandin analogs have repeatedly been described in the litera-
ture for having anti-cancer activities, but their mechanism of action 
has not been clarified before (Fionda et al., 2007; Zimmer et al., 
2010; Hegde et al., 2011). Furthermore, our analysis revealed that 
simvastatin, a cholesterol-lowering drug, has a leukemia-specific 
anti-inflammatory response very similar to a range of corticoster-
oids. This appears to be a significant finding in the light that lovas-
tatin, a close structural analog of simvastatin, recently was shown 
to selectively inhibit leukemic stem cells together with several 
anti-inflammatory steroids (Hartwell et al., 2013). 
Such systematic explorations raise the possibility for targeted  
interventions and will become a growing trend in the future as 
more large-scale datasets like the CMap will become available. For 
drug designers it opens up the opportunity to tailor drug molecules 
to match a desired gene expression fingerprint. For medicinal 
chemists, it could help to increase understanding of action mecha-
nisms of existing drugs and revealing potential on-label and off-
label applications, including precision medicine. 
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Fig. 6. SP2: Corticosteroids showing response specific to HL60 cells, while 
only minor regulation in PC3 and not at all in MCF7. 
